Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)

By virtue of its role in cellular proliferation, microtubule-associated serine/threonine kinase-like (MASTL) represents a novel target and a first-in-class (FIC) opportunity to provide a new impactful therapeutic agent to oncology patients. Herein, we describe a hit-to-lead optimization effort that resulted in the delivery of two highly selective MASTL inhibitors. Key strategies leveraged to enable this work included structure-based drug design (SBDD), analysis of lipophilic efficiency (LipE) and novel synthesis. The resulting advanced lead compounds enabled a tumor growth inhibition study which was pivotal in assessing the potential value of MASTL as an oncology therapeutic target.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-11-05
DOI
https://doi.org/10.1021/acs.jmedchem.4c01659
Citations
5
Primary Topic
Microtubule and mitosis dynamics
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)

Michael Maestre, Angelica Linton, Paul Richardson, Sonja N. Brun et al.
5 citations
Journal of Medicinal Chemistry
Microtubule and mitosis dynamics
1.63
article

Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)

Michael Maestre, Angelica Linton, Paul Richardson, Sonja N. Brun, Eric C. Greenwald, Penney Khamphavong, Louise Bernier, Phương Thu Trần, Koleen Eisele, Francisco J. Silva, Rebecca A. Gallego, Madeline Berry, Ted W. Johnson, S.E. Greasley, Sergei Timofeevski, Neal W. Sach, Nichol Miller, Jason Ewanicki, Todd VanArsdale, Loanne Chung, Martin Wythes, Ryan L. Patman, Dana J. Ramms, Indrawan McAlpine, Jeff Elleraas, Casey L. Quinlan, Yvette M. Fobian, Michelle Tran‐Dubé, Wade Diehl, Klaus Dress, Romelia Salomón–Ferrer, Wei Wang, Jian Li, Fen Wang, Aihua Zou, Marin Auth, Chad M. Toledo, Shouliang Yang, Carl Davis, Stephanie Scales, Jennifer Lafontaine, Anwar Murtaza
article en
5 citations

Abstract

By virtue of its role in cellular proliferation, microtubule-associated serine/threonine kinase-like (MASTL) represents a novel target and a first-in-class (FIC) opportunity to provide a new impactful therapeutic agent to oncology patients. Herein, we describe a hit-to-lead optimization effort that resulted in the delivery of two highly selective MASTL inhibitors. Key strategies leveraged to enable this work included structure-based drug design (SBDD), analysis of lipophilic efficiency (LipE) and novel synthesis. The resulting advanced lead compounds enabled a tumor growth inhibition study which was pivotal in assessing the potential value of MASTL as an oncology therapeutic target.

Journal of Medicinal ChemistryVol. 67(21)
Pfizer (United States) (US)
Openalex Percentile: Top 17%
Microtubule and mitosis dynamics
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.